For years, millions of people struggled with obesity and had very few good options to deal with it. Then came a new group of medicines called GLP-1 drugs. These drugs work by copying a hormone in your body that tells your brain you are full. The results were huge. People started weight loss they had never been able to lose before. But there was one big problem — these medicines were shots. You had to inject yourself once a week. That turned a lot of people away.
Now everything is changing. Drug companies have found a way to put these medicines into a pill that you can swallow. Right now in 2026 some of the biggest names in the medicine field are trying very hard to be the best, at making these medicine pills. The drug companies are working hard to make the best medicine pills.
The Two Giants: Novo Nordisk and Eli Lilly
The two companies leading the pack are Novo Nordisk and Eli Lilly. You may have heard of their injection drugs, Wegovy and Zepbound. These shots became very popular because they helped people lose a serious amount of weight. But now, both companies have launched pill versions too.
Novo Nordisk led the way with its Wegovy pill, which got approved back in December 2025. Just a few months later, Eli Lilly followed with its own pill, called Foundayo. These two new pill options are now going head-to-head in the market.
Why are pills such a big deal? Think about it this way. If you had a choice between taking a shot every week and just swallowing a pill with breakfast, which would you pick? Most people would choose the pill. Injections must be stored and kept cold under specific conditions. Pills are much easier to manage, especially for people who travel a lot. When medicine is easier to take, more people actually take it — and that means better results.
The GLP-1 drug market is projected to reach $100 billion by 2030, so it is not hard to see why these companies are working so fast to get ahead.
Eli Lilly’s Next Big Bet: Retatrutide
Eli Lilly is not stopping with Foundayo. The company is already working on something that could be even more powerful. It is called retatrutide, and it works differently from current drugs. Instead of targeting just one hormone, retatrutide targets three hormones at once: GLP-1, GIP, and glucagon.
Early results from clinical trials — the studies that test whether a drug is safe and effective — are very promising. In one phase 3 trial called Triumph-4, which tested retatrutide in people with obesity and knee joint pain, the high-dose group saw an average reduction in body weight of 28.7%, or roughly 71 pounds, after 68 weeks. To put that in perspective, current popular drugs like Zepbound showed weight loss of around 15 to 20 percent in similar timeframes. That is a massive jump.
Retatrutide also reduced knee pain, with more than 1 in 8 patients reporting they were completely free of that issue by the end of the trial. Another trial showed patients with type 2 diabetes lost an average of 36 pounds and also got better control of their blood sugar levels.
Of course, there are some downsides. Some patients in the trials stopped taking the drug because of stomach-related side effects. And people who were not heavily overweight to begin with sometimes lost too much weight. So this drug may work best for people who have a lot of weight to lose. Still, if all goes well, analysts estimate retatrutide could reach nearly $4 billion in global sales by 2030.
The Dark Horse: Viking Therapeutics
While Novo Nordisk and Eli Lilly have the spotlight, there is a smaller company quietly gaining attention. It is called Viking Therapeutics, and it is working on a drug called VK2735.
Viking’s drug VK2735 is a GLP-1 medicine being developed in both pill and injectable forms. In a phase 2 study, the oral version led to an average weight loss of up to 12.2% at the highest dose in just 13 weeks, and no weight-loss plateau was observed. A plateau is when your weight loss slows down or stops even though you are still taking the medicine. Not seeing one is a good sign.
Viking brings up a point. What happens when patients finally reach their goal weight? How medicine do they still need to take to keep that weight off? This is a question. Losing weight is tough. Keeping it off is just as hard.
However, Viking is not without problems. When the company first reported its phase 2 results for the oral version of VK2735, a high number of patients stopped the trial because of stomach-related side effects. At the highest dose, 38% of patients quit treatment early. That is a serious concern the company will have to fix before the drug can succeed.
Pfizer Joins the Fight
There is one more player entering the game: Pfizer. The company spent $10 billion to acquire a drug called PF’3944, which works differently from the others. Instead of being taken weekly, it could be taken just once a month.
In a recent phase 2 trial, this monthly drug triggered a mean weight loss of up to 12.3% and delivered a favorable safety profile. At 28 weeks, there was no apparent weight-loss plateau. A once-a-month shot is a lot easier to manage than weekly injections, and that could make it very popular with patients.
What Does All This Mean for You
The weight loss drug market is changing faster than ever before. Just a few years ago, the only real option was a weekly injection. Now, there are approved pills, powerful new drugs in clinical trials, and even a monthly injection on the way. Companies are also looking at other health problems these drugs might help with, like knee pain, sleep problems, and diabetes.
Competition is really good for patients. When these drug companies compete with each other they work hard to make their products better, safer and cheaper for people to buy. For all the people who are dealing with obesity this competition could mean they get options they have fewer bad side effects and over time the prices of these products become lower. This is a deal for the millions of people around the world who are dealing with obesity because competition between drug companies can lead to better products and lower prices, for obesity treatments.
The battle for the best weight loss pill is just getting started — and the coming months will tell us a lot about who wins.
